The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two drug discovery approaches. The first approach is our TMAb™️ (Tumor Microenvironment Activated biologics) platform comprised of human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. Our lead program is targeting VISTA, a promising immune checkpoint inhibitor expressed on myeloid cells. Emerging nonclinical evidence has demonstrated that interaction of VISTA with its receptor (PSGL-1) is significantly enhanced by the acidic tumor microenvironment – a important differentiator of our research. We’re focused on unlocking the potential of VISTA with a human antibody and designed SNS-101 that selectively binds VISTA at low pH to activate T-cells and avoids on-target/off-tumor side effects, in preclinical studies.

The second approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Robert Pierce, M.D.

Chief Scientific Officer

John K. Celebi, M.B.A.

President and CEO

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

     -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cellRead More

  • Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index

    BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000® IndexRead More

  • Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

    BOSTON and ROCKVILLE, Md. , March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi , President and Chief Executive Officer ofRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics Reports Full Year 2020 Results and Provides Business Update

     -Successfully completed upsized IPO in February 2021 raising approximately $152.6 million in gross proceeds – -Large subset of data expected from ongoing Phase 1/2 study of SNS-301 in combination with pembrolizumab for the treatment of locally advanced unresectable or metastatic squamous cellRead More

  • Sensei Biotherapeutics Announces Inclusion in Russell 2000 Index

    BOSTON and ROCKVILLE, Md., March 22, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it will be added to the Russell 2000® IndexRead More

  • Sensei Biotherapeutics to Present at Oppenheimer 31st Annual Virtual Healthcare Conference

    BOSTON and ROCKVILLE, Md. , March 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi , President and Chief Executive Officer ofRead More

Signup For Update

sign up for newsletter and get the latest update